Cognitive function enhancer

Cognitive function enhancers, often referred to as nootropics or smart drugs, represent a broad and diverse category of substances intended to improve mental performance, including memory, motivation, and attention (Froestl et al., 2012; PubMed). This term does not identify a single molecular target or receptor but rather a therapeutic outcome achieved through various pharmacological pathways involving the cholinergic, glutamatergic, and dopaminergic systems (StatPearls, 2023). Common examples include cholinesterase inhibitors used to manage Alzheimer's disease and psychostimulants used for treating ADHD (NIH, 2021). These agents generally aim to optimize synaptic plasticity, enhance neuroenergetics, or provide neuroprotective effects within the central nervous system (Journal of Clinical Medicine, 2019). Because it is a functional classification rather than a specific biological entity like a protein or enzyme, it is considered 'incorrect' as a singular molecular target (UniProt). The use of these enhancers in healthy populations raises significant ethical concerns and potential safety risks, such as cardiovascular stress and psychiatric side effects (PubMed, 2022). Consequently, researchers focus on specific molecular targets within this category, such as the Alpha-7 nicotinic receptor or Phosphodiesterase-4, rather than the broad functional descriptor itself.

Other names

NootropicCognitive enhancerSmart drugNeuroenhancerMemory enhancer

The mechanism of action for cognitive function enhancers is highly heterogeneous and depends on the specific drug class; it typically involves increasing the concentration of neurotransmitters such as acetylcholine, dopamine, or glutamate, modulating ionotropic receptors (e.g., NMDA or AMPA receptors) to facilitate long-term potentiation, or improving cerebral metabolic activity (StatPearls, 2023; PubMed, 2020).